AdAlta Limited (ASX:1AD) to Present at Biotech Showcase 2025
Event Overview
AdAlta Limited (ASX:1AD), a developer of novel protein and cell therapeutic products, will present at Biotech Showcase 2025 as part of JPMorgan Healthcare Week. The event is significant for the biotech sector, connecting investors and innovators.
Presentation Highlights
CEO and Managing Director Dr Tim Oldham will discuss AdAlta’s “East to West” cellular immunotherapy growth strategy. The presentation will highlight the lead asset, AD-214, aimed at fibrotic diseases including Idiopathic Pulmonary Fibrosis (IPF). AD-214 is now available for partnering and co-development investment.
Details of the Presentation
The presentation titled “Developing novel protein and cell therapeutics for fatal diseases” will take place on 13 January 2025 at 4:00 PM US Pacific Time (11:00 AM AEST on 14 January) at the Hilton Hotel in San Francisco. A video of the presentation will be available, along with opportunities for virtual discussion.
Future Outlook
AdAlta’s growth strategy focusses on leveraging its proprietary i-body® technology to enhance therapeutic options for patients facing serious medical conditions. The Company is committed to advancing its position within the competitive biotech landscape and fostering strategic partnerships.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.